{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T13:05:18Z","timestamp":1773666318519,"version":"3.50.1"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100007131","name":"Changzhou Municipal Science and Technology Bureau","doi-asserted-by":"crossref","award":["CJ20253108"],"award-info":[{"award-number":["CJ20253108"]}],"id":[{"id":"10.13039\/501100007131","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-11681-6","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T11:31:02Z","timestamp":1773660662000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The dual role of pyroptosis in prostate cancer: new perspectives from molecular mechanisms to clinical translation"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7650-8842","authenticated-orcid":false,"given":"Wenjian","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"issue":"3","key":"11681_CR1","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.eururo.2024.11.013","volume":"87","author":"EJ Schafer","year":"2025","unstructured":"Schafer EJ, Laversanne M, Sung H, Soerjomataram I, Briganti A, Dahut W et al (2025) Recent patterns and trends in global prostate cancer incidence and mortality: an update. Eur Urol 87(3):302\u2013313","journal-title":"Eur Urol"},{"issue":"1","key":"11681_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","volume":"7","author":"RJ Rebello","year":"2021","unstructured":"Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE et al (2021) Prostate cancer. Nat Rev Dis Primers 7(1):9","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"11681_CR3","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A (2025) Cancer statistics, 2025. CA Cancer J Clin 75(1):10\u201345","journal-title":"CA Cancer J Clin"},{"key":"11681_CR4","doi-asserted-by":"crossref","unstructured":"Li J, Wu Y, Hou J, Liu H, Wang Y, Zhang F et al (2025) A comparative study of the global burden of prostate cancer (1990\u20132021): Emphasis on the Disparities Between the United States and China. Prostate 86(4):451-463","DOI":"10.1002\/pros.70104"},{"issue":"5","key":"11681_CR5","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.21037\/tau-2025-103","volume":"14","author":"X Lin","year":"2025","unstructured":"Lin X, Zhi Y (2025) Global epidemiological trends in prostate cancer burden: a comprehensive analysis from Global Burden of Disease Study 2021. Transl Androl Urol 14(5):1238\u20131252","journal-title":"Transl Androl Urol"},{"issue":"2","key":"11681_CR6","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","volume":"86","author":"D Tilki","year":"2024","unstructured":"Tilki D, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J et al (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II-2024 update: treatment of relapsing and metastatic prostate cancer. Eur Urol 86(2):164\u2013182","journal-title":"Eur Urol"},{"key":"11681_CR7","doi-asserted-by":"publisher","first-page":"103064","DOI":"10.1016\/j.ctrv.2025.103064","volume":"142","author":"F Petrelli","year":"2025","unstructured":"Petrelli F, Trevisan F, Bruschieri L, Riboldi V, Vavassori I, Seghezzi S et al (2025) Primary tumor and metastasis-directed treatment for oligometastatic prostate cancer: An umbrella review of meta-analyses. Cancer Treat Rev 142:103064","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"11681_CR8","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41585-019-0237-8","volume":"16","author":"SY Ku","year":"2019","unstructured":"Ku SY, Gleave ME, Beltran H (2019) Towards precision oncology in advanced prostate cancer. Nat Rev Urol 16(11):645\u2013654","journal-title":"Nat Rev Urol"},{"key":"11681_CR9","doi-asserted-by":"crossref","unstructured":"Al-Khanaty A, Hennes D, Perera ML, Lawrentschuk N, Murphy DG, Eapen RS (2026) Neoadjuvant systemic therapy in high-risk localised prostate cancer: current evidence and future directions. Eur Urol Focus 12(1):24-27","DOI":"10.1016\/j.euf.2025.11.016"},{"key":"11681_CR10","doi-asserted-by":"crossref","unstructured":"Bader DA, Chakraborty B, McDonnell DP, Hirschey MD (2025) Targeting androgen receptor signaling to enhance cancer immunotherapy. Trends Pharmacol SciS0165-6147(25)00257-3","DOI":"10.1016\/j.tips.2025.11.003"},{"issue":"5","key":"11681_CR11","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/s41422-025-01107-6","volume":"35","author":"P Broz","year":"2025","unstructured":"Broz P (2025) Pyroptosis: molecular mechanisms and roles in disease. Cell Res 35(5):334\u2013344","journal-title":"Cell Res"},{"issue":"1","key":"11681_CR12","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41392-021-00507-5","volume":"6","author":"P Yu","year":"2021","unstructured":"Yu P, Zhang X, Liu N, Tang L, Peng C, Chen X (2021) Pyroptosis: mechanisms and diseases. Signal Transduct Target Ther 6(1):128","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"11681_CR13","doi-asserted-by":"publisher","first-page":"4310","DOI":"10.7150\/thno.71086","volume":"12","author":"Z Rao","year":"2022","unstructured":"Rao Z, Zhu Y, Yang P, Chen Z, Xia Y, Qiao C et al (2022) Pyroptosis in inflammatory diseases and cancer. Theranostics 12(9):4310\u20134329","journal-title":"Theranostics"},{"issue":"9","key":"11681_CR14","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/s41423-022-00905-x","volume":"19","author":"X Wei","year":"2022","unstructured":"Wei X, Xie F, Zhou X, Wu Y, Yan H, Liu T et al (2022) Role of pyroptosis in inflammation and cancer. Cell Mol Immunol 19(9):971\u2013992","journal-title":"Cell Mol Immunol"},{"issue":"7661","key":"11681_CR15","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nature22393","volume":"547","author":"Y Wang","year":"2017","unstructured":"Wang Y, Gao W, Shi X, Ding J, Liu W, He H et al (2017) Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. Nature 547(7661):99\u2013103","journal-title":"Nature"},{"issue":"10","key":"11681_CR16","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1038\/s41401-022-00887-6","volume":"43","author":"F Yang","year":"2022","unstructured":"Yang F, Bettadapura SN, Smeltzer MS, Zhu H, Wang S (2022) Pyroptosis and pyroptosis-inducing cancer drugs. Acta Pharmacol Sin 43(10):2462\u20132473","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"11681_CR17","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s13046-021-02065-8","volume":"40","author":"R Loveless","year":"2021","unstructured":"Loveless R, Bloomquist R, Teng Y (2021) Pyroptosis at the forefront of anticancer immunity. J Exp Clin Cancer Res 40(1):264","journal-title":"J Exp Clin Cancer Res"},{"key":"11681_CR18","doi-asserted-by":"publisher","first-page":"121498","DOI":"10.1016\/j.lfs.2023.121498","volume":"318","author":"Z Liu","year":"2023","unstructured":"Liu Z, Wang C, Lin C (2023) Pyroptosis as a double-edged sword: The pathogenic and therapeutic roles in inflammatory diseases and cancers. Life Sci 318:121498","journal-title":"Life Sci"},{"issue":"1","key":"11681_CR19","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s12943-025-02491-8","volume":"24","author":"H Zhang","year":"2025","unstructured":"Zhang H, Li S, Liu S, Liao Y, Liu H, Yang M et al (2025) Therapeutic targeting of cell death-immune crosstalk in cancer to rewire the tumor immune microenvironment. Mol Cancer 24(1):277","journal-title":"Mol Cancer"},{"issue":"2","key":"11681_CR20","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.cell.2024.11.018","volume":"188","author":"SS Wright","year":"2025","unstructured":"Wright SS, Kumari P, Fraile-\u00c1greda V, Wang C, Shivcharan S, Kappelhoff S et al (2025) Transplantation of gasdermin pores by extracellular vesicles propagates pyroptosis to bystander cells. Cell 188(2):280\u2013 \u2013\u200991.e17","journal-title":"Cell"},{"issue":"7575","key":"11681_CR21","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/nature15541","volume":"526","author":"N Kayagaki","year":"2015","unstructured":"Kayagaki N, Stowe IB, Lee BL, O\u2019Rourke K, Anderson K, Warming S et al (2015) Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. Nature 526(7575):666\u2013671","journal-title":"Nature"},{"issue":"3\u20134","key":"11681_CR22","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s10495-019-01515-1","volume":"24","author":"CC Zhang","year":"2019","unstructured":"Zhang CC, Li CG, Wang YF, Xu LH, He XH, Zeng QZ et al (2019) Chemotherapeutic paclitaxel and cisplatin differentially induce pyroptosis in A549 lung cancer cells via caspase-3\/GSDME activation. Apoptosis 24(3\u20134):312\u2013325","journal-title":"Apoptosis"},{"issue":"3","key":"11681_CR23","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41577-019-0228-2","volume":"20","author":"P Broz","year":"2020","unstructured":"Broz P, Pelegr\u00edn P, Shao F (2020) The gasdermins, a protein family executing cell death and inflammation. Nat Rev Immunol 20(3):143\u2013157","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"11681_CR24","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12964-023-01458-w","volume":"22","author":"X Liang","year":"2024","unstructured":"Liang X, Qin Y, Wu D, Wang Q, Wu H (2024) Pyroptosis: a double-edged sword in lung cancer and other respiratory diseases. Cell Commun Signal 22(1):40","journal-title":"Cell Commun Signal"},{"issue":"9","key":"11681_CR25","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/s41556-024-01474-z","volume":"26","author":"KW Chen","year":"2024","unstructured":"Chen KW, Broz P (2024) Gasdermins as evolutionarily conserved executors of inflammation and cell death. Nat Cell Biol 26(9):1394\u20131406","journal-title":"Nat Cell Biol"},{"issue":"1","key":"11681_CR26","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-025-02344-4","volume":"24","author":"C Huang","year":"2025","unstructured":"Huang C, Li J, Wu R, Li Y, Zhang C (2025) Targeting pyroptosis for cancer immunotherapy: mechanistic insights and clinical perspectives. Mol Cancer 24(1):131","journal-title":"Mol Cancer"},{"issue":"7","key":"11681_CR27","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41580-025-00837-0","volume":"26","author":"Y Bai","year":"2025","unstructured":"Bai Y, Pan Y, Liu X (2025) Mechanistic insights into gasdermin-mediated pyroptosis. Nat Rev Mol Cell Biol 26(7):501\u2013521","journal-title":"Nat Rev Mol Cell Biol"},{"key":"11681_CR28","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.3389\/fimmu.2020.01647","volume":"11","author":"JV Alves","year":"2020","unstructured":"Alves JV, da Costa RM, Pereira CA, Fedoce AG, Silva CAA, Carneiro FS et al (2020) Supraphysiological levels of testosterone induce vascular dysfunction via activation of the NLRP3 inflammasome. Front Immunol 11:1647","journal-title":"Front Immunol"},{"issue":"11","key":"11681_CR29","doi-asserted-by":"publisher","first-page":"e22602","DOI":"10.1096\/fj.202200673RRR","volume":"36","author":"AN Zhao","year":"2022","unstructured":"Zhao AN, Yang Z, Wang DD, Shi B, Zhang H, Bai Y et al (2022) Disturbing NLRP3 acetylation and inflammasome assembly inhibits androgen receptor-promoted inflammatory responses and prostate cancer progression. Faseb j 36(11):e22602","journal-title":"Faseb j"},{"key":"11681_CR30","doi-asserted-by":"crossref","unstructured":"Bas\u00edlio J, Hochreiter B, Hoesel B, Sheshori E, Mussbacher M, Hanel R et al (2022) Antagonistic functions of androgen receptor and NF-\u03baB in prostate cancer-experimental and computational analyses. Cancers (Basel) 14(24):6164","DOI":"10.3390\/cancers14246164"},{"issue":"6","key":"11681_CR31","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/s41556-020-0510-3","volume":"22","author":"Y Huang","year":"2020","unstructured":"Huang Y, Wang H, Hao Y, Lin H, Dong M, Ye J et al (2020) Myeloid PTEN promotes chemotherapy-induced NLRP3-inflammasome activation and antitumour immunity. Nat Cell Biol 22(6):716\u2013727","journal-title":"Nat Cell Biol"},{"issue":"1","key":"11681_CR32","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s13046-024-03168-8","volume":"43","author":"W Chen","year":"2024","unstructured":"Chen W, Yang KB, Zhang YZ, Lin ZS, Chen JW, Qi SF et al (2024) Synthetic lethality of combined ULK1 defection and p53 restoration induce pyroptosis by directly upregulating GSDME transcription and cleavage activation through ROS\/NLRP3 signaling. J Exp Clin Cancer Res 43(1):248","journal-title":"J Exp Clin Cancer Res"},{"key":"11681_CR33","doi-asserted-by":"publisher","first-page":"101587","DOI":"10.1016\/j.molmet.2022.101587","volume":"65","author":"C Huang","year":"2022","unstructured":"Huang C, Li J, Zhang C (2022) What role does pyroptosis play in cancer? Mol Metab 65:101587","journal-title":"Mol Metab"},{"issue":"12","key":"11681_CR34","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/s41419-023-06382-y","volume":"14","author":"Y Hu","year":"2023","unstructured":"Hu Y, Liu Y, Zong L, Zhang W, Liu R, Xing Q et al (2023) The multifaceted roles of GSDME-mediated pyroptosis in cancer: therapeutic strategies and persisting obstacles. Cell Death Dis 14(12):836","journal-title":"Cell Death Dis"},{"issue":"8","key":"11681_CR35","doi-asserted-by":"publisher","first-page":"e492","DOI":"10.1002\/ctm2.492","volume":"11","author":"T Du","year":"2021","unstructured":"Du T, Gao J, Li P, Wang Y, Qi Q, Liu X et al (2021) Pyroptosis, metabolism, and tumor immune microenvironment. Clin Transl Med 11(8):e492","journal-title":"Clin Transl Med"},{"key":"11681_CR36","doi-asserted-by":"publisher","first-page":"5545","DOI":"10.2147\/IJN.S457309","volume":"19","author":"F Ji","year":"2024","unstructured":"Ji F, Shi C, Shu Z, Li Z (2024) Nanomaterials Enhance Pyroptosis-Based Tumor Immunotherapy. Int J Nanomed 19:5545\u20135579","journal-title":"Int J Nanomed"},{"key":"11681_CR37","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.canlet.2019.11.009","volume":"470","author":"X Lei","year":"2020","unstructured":"Lei X, Lei Y, Li JK, Du WX, Li RG, Yang J et al (2020) Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy. Cancer Lett 470:126\u2013133","journal-title":"Cancer Lett"},{"issue":"1","key":"11681_CR38","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s40164-023-00428-9","volume":"12","author":"F Wu","year":"2023","unstructured":"Wu F, Wang M, Zhong T, Xiao C, Chen X, Huang Y et al (2023) Inhibition of CDC20 potentiates anti-tumor immunity through facilitating GSDME-mediated pyroptosis in prostate cancer. Exp Hematol Oncol 12(1):67","journal-title":"Exp Hematol Oncol"},{"issue":"6","key":"11681_CR39","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1007\/s13402-023-00860-3","volume":"46","author":"A Tian","year":"2023","unstructured":"Tian A, Wu T, Zhang Y, Chen J, Sha J, Xia W (2023) Triggering pyroptosis enhances the antitumor efficacy of PARP inhibitors in prostate cancer. Cell Oncol (Dordr) 46(6):1855\u20131870","journal-title":"Cell Oncol (Dordr)"},{"issue":"7799","key":"11681_CR40","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41586-020-2071-9","volume":"579","author":"Z Zhang","year":"2020","unstructured":"Zhang Z, Zhang Y, Xia S, Kong Q, Li S, Liu X et al (2020) Gasdermin E suppresses tumour growth by activating anti-tumour immunity. Nature 579(7799):415\u2013420","journal-title":"Nature"},{"issue":"1","key":"11681_CR41","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s11033-023-09132-7","volume":"51","author":"Y Zeng","year":"2024","unstructured":"Zeng Y, Li MX, Wu SQ, Xu C (2024) Carvedilol induces pyroptosis through NLRP3-caspase1-ASC inflammasome by nuclear migration of NF-\u03baB in prostate cancer models. Mol Biol Rep 51(1):201","journal-title":"Mol Biol Rep"},{"key":"11681_CR42","doi-asserted-by":"crossref","unstructured":"Ju M, Bi J, Wei Q, Jiang L, Guan Q, Zhang M et al (2021) Pan-cancer analysis of NLRP3 inflammasome with potential implications in prognosis and immunotherapy in human cancer. Brief Bioinform 22(4):bbaa345","DOI":"10.1093\/bib\/bbaa345"},{"issue":"5","key":"11681_CR43","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/s41590-021-00886-5","volume":"22","author":"BR Sharma","year":"2021","unstructured":"Sharma BR, Kanneganti TD (2021) NLRP3 inflammasome in cancer and metabolic diseases. Nat Immunol 22(5):550\u2013559","journal-title":"Nat Immunol"},{"key":"11681_CR44","doi-asserted-by":"publisher","first-page":"1611719","DOI":"10.3389\/fimmu.2025.1611719","volume":"16","author":"S Malvankar","year":"2025","unstructured":"Malvankar S, Jaiswal P, Bhat PP, Mehto S (2025) Regulation of cancer by inflammasomes: from inflammation to tumorigenesis. Front Immunol 16:1611719","journal-title":"Front Immunol"},{"key":"11681_CR45","doi-asserted-by":"publisher","first-page":"698811","DOI":"10.3389\/fonc.2021.698811","volume":"11","author":"D Wu","year":"2021","unstructured":"Wu D, Wei C, Li Y, Yang X, Zhou S (2021) Pyroptosis, a New Breakthrough in Cancer Treatment. Front Oncol 11:698811","journal-title":"Front Oncol"},{"key":"11681_CR46","doi-asserted-by":"publisher","first-page":"1593774","DOI":"10.3389\/fonc.2025.1593774","volume":"15","author":"W Sun","year":"2025","unstructured":"Sun W, Ma R, Zhao R, Tian J, Liu W (2025) The NLRP3 inflammasome in urogenital cancers: structure, dual function, and therapeutic potential. Front Oncol 15:1593774","journal-title":"Front Oncol"},{"issue":"8","key":"11681_CR47","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41568-020-0267-9","volume":"20","author":"JS de Bono","year":"2020","unstructured":"de Bono JS, Guo C, Gurel B, De Marzo AM, Sfanos KS, Mani RS et al (2020) Prostate carcinogenesis: inflammatory storms. Nat Rev Cancer 20(8):455\u2013469","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"11681_CR48","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1038\/s41416-021-01537-0","volume":"125","author":"H Yu","year":"2021","unstructured":"Yu H, Xie M, Meng Z, Lo CY, Chan FL, Jiang L et al (2021) Endolysosomal ion channel MCOLN2 (Mucolipin-2) promotes prostate cancer progression via IL-1\u03b2\/NF-\u03baB pathway. Br J Cancer 125(10):1420\u20131431","journal-title":"Br J Cancer"},{"key":"11681_CR49","doi-asserted-by":"crossref","unstructured":"Chen Z, Giotti B, Kaluzova M, Vallcorba MP, Rawat K, Price G et al (2023) A paracrine circuit of IL-1\u03b2\/IL-1R1 between myeloid and tumor cells drives genotype-dependent glioblastoma progression. J Clin Invest 133(22):e163802","DOI":"10.1172\/JCI163802"},{"issue":"2","key":"11681_CR50","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.cyto.2013.09.003","volume":"64","author":"G Rodr\u00edguez-Berriguete","year":"2013","unstructured":"Rodr\u00edguez-Berriguete G, S\u00e1nchez-Espiridi\u00f3n B, Cansino JR, Olmedilla G, Mart\u00ednez-Onsurbe P, S\u00e1nchez-Chapado M et al (2013) Clinical significance of both tumor and stromal expression of components of the IL-1 and TNF-\u03b1 signaling pathways in prostate cancer. Cytokine 64(2):555\u2013563","journal-title":"Cytokine"},{"issue":"10","key":"11681_CR51","doi-asserted-by":"publisher","first-page":"e45986","DOI":"10.15252\/embr.201845986","volume":"20","author":"YH Wang","year":"2019","unstructured":"Wang YH, Huang JT, Chen WL, Wang RH, Kao MC, Pan YR et al (2019) Dysregulation of cystathionine \u03b3-lyase promotes prostate cancer progression and metastasis. EMBO Rep 20(10):e45986","journal-title":"EMBO Rep"},{"issue":"1","key":"11681_CR52","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13045-019-0760-3","volume":"12","author":"Y Lin","year":"2019","unstructured":"Lin Y, Xu J, Lan H (2019) Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications. J Hematol Oncol 12(1):76","journal-title":"J Hematol Oncol"},{"key":"11681_CR53","doi-asserted-by":"publisher","first-page":"117002","DOI":"10.1016\/j.biopha.2024.117002","volume":"177","author":"Q Gu","year":"2024","unstructured":"Gu Q, Qi A, Wang N, Zhou Z, Zhou X (2024) Macrophage dynamics in prostate cancer: Molecular to therapeutic insights. Biomed Pharmacother 177:117002","journal-title":"Biomed Pharmacother"},{"issue":"10","key":"11681_CR54","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41585-021-00490-0","volume":"18","author":"Y Wang","year":"2021","unstructured":"Wang Y, Wang Y, Ci X, Choi SYC, Crea F, Lin D et al (2021) Molecular events in neuroendocrine prostate cancer development. Nat Rev Urol 18(10):581\u2013596","journal-title":"Nat Rev Urol"},{"key":"11681_CR55","doi-asserted-by":"publisher","first-page":"108255","DOI":"10.1016\/j.pharmthera.2022.108255","volume":"238","author":"BR Alabi","year":"2022","unstructured":"Alabi BR, Liu S, Stoyanova T (2022) Current and emerging therapies for neuroendocrine prostate cancer. Pharmacol Ther 238:108255","journal-title":"Pharmacol Ther"},{"issue":"3","key":"11681_CR56","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.7150\/thno.92336","volume":"14","author":"T Zhang","year":"2024","unstructured":"Zhang T, Zhao F, Lin Y, Liu M, Zhou H, Cui F et al (2024) Integrated analysis of single-cell and bulk transcriptomics develops a robust neuroendocrine cell-intrinsic signature to predict prostate cancer progression. Theranostics 14(3):1065\u20131080","journal-title":"Theranostics"},{"issue":"1","key":"11681_CR57","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41420-024-02105-0","volume":"10","author":"D Yu","year":"2024","unstructured":"Yu D, Wang S, Wang J, Zhang K, Niu Z, Lin N (2024) EZH2-STAT3 signaling pathway regulates GSDMD-mediated pyroptosis in glioblastoma. Cell Death Discov 10(1):341","journal-title":"Cell Death Discov"},{"key":"11681_CR58","doi-asserted-by":"publisher","first-page":"217155","DOI":"10.1016\/j.canlet.2024.217155","volume":"601","author":"D Liu","year":"2024","unstructured":"Liu D, Wang L, Guo Y (2024) Advances in and prospects of immunotherapy for prostate cancer. Cancer Lett 601:217155","journal-title":"Cancer Lett"},{"issue":"8","key":"11681_CR59","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/s41401-020-0374-x","volume":"41","author":"XM Wei","year":"2020","unstructured":"Wei XM, Wumaier G, Zhu N, Dong L, Li CW, Xia JW et al (2020) Protein tyrosine phosphatase L1 represses endothelial-mesenchymal transition by inhibiting IL-1\u03b2\/NF-\u03baB\/Snail signaling. Acta Pharmacol Sin 41(8):1102\u20131110","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"11681_CR60","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40164-024-00529-z","volume":"13","author":"Q Ma","year":"2024","unstructured":"Ma Q, Hao S, Hong W, Tergaonkar V, Sethi G, Tian Y et al (2024) Versatile function of NF-\u0138B in inflammation and cancer. Exp Hematol Oncol 13(1):68","journal-title":"Exp Hematol Oncol"},{"key":"11681_CR61","doi-asserted-by":"crossref","unstructured":"El-Far AH, Sroga G, Jaouni SKA, Mousa SA (2020) Role and mechanisms of RAGE-ligand complexes and RAGE-inhibitors in cancer progression. Int J Mol Sci 21(10):3613","DOI":"10.3390\/ijms21103613"},{"key":"11681_CR62","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.3389\/fimmu.2019.01426","volume":"10","author":"E Fahey","year":"2019","unstructured":"Fahey E, Doyle SL (2019) IL-1 Family cytokine regulation of vascular permeability and angiogenesis. Front Immunol 10:1426","journal-title":"Front Immunol"},{"key":"11681_CR63","doi-asserted-by":"publisher","first-page":"1478331","DOI":"10.3389\/fphar.2025.1478331","volume":"16","author":"X Li","year":"2025","unstructured":"Li X, Yang F, Wang M, Huang X, Zeng X, Zhou L et al (2025) Unleashing the power of peptides in prostate cancer immunotherapy: mechanism, facts and perspectives. Front Pharmacol 16:1478331","journal-title":"Front Pharmacol"},{"issue":"22","key":"11681_CR64","doi-asserted-by":"publisher","first-page":"e2408996","DOI":"10.1002\/smll.202408996","volume":"21","author":"X Chen","year":"2025","unstructured":"Chen X, Kadier M, Shi M, Li K, Chen H, Xia Y et al (2025) Targeting Melatonin to Mitochondria Mitigates Castration-Resistant Prostate Cancer by Inducing Pyroptosis. Small 21(22):e2408996","journal-title":"Small"},{"issue":"1","key":"11681_CR65","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12943-023-01801-2","volume":"22","author":"Y Wu","year":"2023","unstructured":"Wu Y, Song Y, Wang R, Wang T (2023) Molecular mechanisms of tumor resistance to radiotherapy. Mol Cancer 22(1):96","journal-title":"Mol Cancer"},{"key":"11681_CR66","doi-asserted-by":"publisher","first-page":"100742","DOI":"10.1016\/j.drup.2020.100742","volume":"54","author":"L Mosca","year":"2021","unstructured":"Mosca L, Ilari A, Fazi F, Assaraf YG, Colotti G (2021) Taxanes in cancer treatment: Activity, chemoresistance and its overcoming. Drug Resist Updat 54:100742","journal-title":"Drug Resist Updat"},{"key":"11681_CR67","doi-asserted-by":"publisher","first-page":"109689","DOI":"10.1016\/j.radonc.2023.109689","volume":"184","author":"Y Wang","year":"2023","unstructured":"Wang Y, Wang Y, Pan J, Gan L, Xue J (2023) Ferroptosis, necroptosis, and pyroptosis in cancer: Crucial cell death types in radiotherapy and post-radiotherapy immune activation. Radiother Oncol 184:109689","journal-title":"Radiother Oncol"},{"issue":"5","key":"11681_CR68","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.trecan.2023.02.001","volume":"9","author":"K H\u00e4nggi","year":"2023","unstructured":"H\u00e4nggi K, Ruffell B (2023) Cell death, therapeutics, and the immune response in cancer. Trends Cancer 9(5):381\u2013396","journal-title":"Trends Cancer"},{"key":"11681_CR69","doi-asserted-by":"crossref","unstructured":"Liu R, Zhang L, Xie G, Li X, Liu Y, Li N et al (2025) Docetaxel induced activation of GSDME pathway and pyroptosis enhance immune lethality in prostate cancer cells. J Exp Clin Cancer Res 45(1):22","DOI":"10.1186\/s13046-025-03614-1"},{"issue":"1","key":"11681_CR70","doi-asserted-by":"publisher","first-page":"2333790","DOI":"10.1080\/19490976.2024.2333790","volume":"16","author":"N Wang","year":"2024","unstructured":"Wang N, Zhang L, Leng XX, Xie YL, Kang ZR, Zhao LC et al (2024) Fusobacterium nucleatum induces chemoresistance in colorectal cancer by inhibiting pyroptosis via the Hippo pathway. Gut Microbes 16(1):2333790","journal-title":"Gut Microbes"},{"issue":"1","key":"11681_CR71","doi-asserted-by":"publisher","first-page":"5300","DOI":"10.1038\/s41467-024-49675-2","volume":"15","author":"SY Huang","year":"2024","unstructured":"Huang SY, Gong S, Zhao Y, Ye ML, Li JY, He QM et al (2024) PJA1-mediated suppression of pyroptosis as a driver of docetaxel resistance in nasopharyngeal carcinoma. Nat Commun 15(1):5300","journal-title":"Nat Commun"},{"issue":"22","key":"11681_CR72","doi-asserted-by":"publisher","first-page":"6165","DOI":"10.1016\/j.cell.2024.08.007","volume":"187","author":"P Fontana","year":"2024","unstructured":"Fontana P, Du G, Zhang Y, Zhang H, Vora SM, Hu JJ et al (2024) Small-molecule GSDMD agonism in tumors stimulates antitumor immunity without toxicity. Cell 187(22):6165\u201381e22","journal-title":"Cell"},{"issue":"7","key":"11681_CR73","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1158\/0008-5472.CAN-22-1812","volume":"83","author":"Y Ren","year":"2023","unstructured":"Ren Y, Feng M, Hao X, Liu X, Li J, Li P et al (2023) USP48 Stabilizes gasdermin E to promote pyroptosis in cancer. Cancer Res 83(7):1074\u20131093","journal-title":"Cancer Res"},{"issue":"5","key":"11681_CR74","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.cell.2020.02.002","volume":"180","author":"K Wang","year":"2020","unstructured":"Wang K, Sun Q, Zhong X, Zeng M, Zeng H, Shi X et al (2020) Structural mechanism for GSDMD targeting by autoprocessed caspases in pyroptosis. Cell 180(5):941\u201355e20","journal-title":"Cell"},{"key":"11681_CR75","doi-asserted-by":"publisher","first-page":"105748","DOI":"10.1016\/j.phrs.2021.105748","volume":"170","author":"R Yuan","year":"2021","unstructured":"Yuan R, Zhao W, Wang QQ, He J, Han S, Gao H et al (2021) Cucurbitacin B inhibits non-small cell lung cancer in vivo and in vitro by triggering TLR4\/NLRP3\/GSDMD-dependent pyroptosis. Pharmacol Res 170:105748","journal-title":"Pharmacol Res"},{"issue":"1","key":"11681_CR76","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41420-025-02516-7","volume":"11","author":"N Miao","year":"2025","unstructured":"Miao N, Kang Z, Wang Z, Yu W, Liu T, Kong LZ et al (2025) Mitochondrial reactive oxygen species promote cancer metastasis and tumor microenvironment immunosuppression through gasdermin D. Cell Death Discov 11(1):219","journal-title":"Cell Death Discov"},{"key":"11681_CR77","doi-asserted-by":"crossref","unstructured":"Li L, Zhao L, Zhou D, Yu Y, Zhang P, Zheng J et al (2025) Targeting pyroptosis reverses KIAA1199-mediated immunotherapy resistance in colorectal cancer. J Immunother Cancer 13(2):e010000","DOI":"10.1136\/jitc-2024-010000"},{"key":"11681_CR78","doi-asserted-by":"crossref","unstructured":"Wittwer NL, Staudacher AH, Liapis V, Cardarelli P, Warren H, Brown MP (2023) An anti-mesothelin targeting antibody drug conjugate induces pyroptosis and ignites antitumor immunity in mouse models of cancer. J Immunother Cancer 11(3):e006274","DOI":"10.1136\/jitc-2022-006274"},{"issue":"3","key":"11681_CR79","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/jleuko\/qiae055","volume":"116","author":"C Gong","year":"2024","unstructured":"Gong C, Mu H, Luo J, Zhang R, Hu D, Chen Z et al (2024) Euphohelioscopin A enhances NK cell antitumor immunity through GSDME-triggered pyroptosis. J Leukoc Biol 116(3):621\u2013631","journal-title":"J Leukoc Biol"},{"issue":"1","key":"11681_CR80","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1186\/s12935-025-04071-8","volume":"25","author":"Y Yan","year":"2025","unstructured":"Yan Y, Xu Z, Wang C, Liu Y, Long Y, Yuan X et al (2025) Natural compound triptolide induces caspase-3\/GSDME-mediated pyroptosis by promoting ROS accumulation in small cell lung cancer. Cancer Cell Int 25(1):426","journal-title":"Cancer Cell Int"},{"key":"11681_CR81","doi-asserted-by":"crossref","unstructured":"Sun J, Li S, Duan Z, Yu H, Zhang J, Xue J et al (2025) Xanthohumol triggers pyroptotic in prostate cancer cells via the caspase-3\/GSDME signaling pathway. Int J Mol Sci 26(21):10347","DOI":"10.3390\/ijms262110347"},{"issue":"1","key":"11681_CR82","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41467-023-35917-2","volume":"14","author":"J Lin","year":"2023","unstructured":"Lin J, Sun S, Zhao K, Gao F, Wang R, Li Q et al (2023) Oncolytic Parapoxvirus induces Gasdermin E-mediated pyroptosis and activates antitumor immunity. Nat Commun 14(1):224","journal-title":"Nat Commun"},{"key":"11681_CR83","doi-asserted-by":"crossref","unstructured":"Zhou Y, Zhang W, Wang B, Wang P, Li D, Cao T et al (2024) Mitochondria-targeted photodynamic therapy triggers GSDME-mediated pyroptosis and sensitizes anti-PD-1 therapy in colorectal cancer. J Immunother Cancer 12(3):e008054","DOI":"10.1136\/jitc-2023-008054"},{"issue":"1","key":"11681_CR84","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s42003-025-08130-8","volume":"8","author":"H Jin","year":"2025","unstructured":"Jin H, Wu P, Lv C, Zhang S, Zhang Y, Li C et al (2025) Mannose inhibits PKM2 lactylation to induce pyroptosis in bladder cancer and activate antitumor immune responses. Commun Biol 8(1):689","journal-title":"Commun Biol"},{"issue":"9","key":"11681_CR85","doi-asserted-by":"publisher","first-page":"102291","DOI":"10.1016\/j.xcrm.2025.102291","volume":"6","author":"X Sun","year":"2025","unstructured":"Sun X, Cai X, Li S, Pi R, Guo Z, Jiang J et al (2025) High-dose ascorbic acid selectively induces pyroptosis in LKB1-deficient lung cancer and sensitizes immunotherapy. Cell Rep Med 6(9):102291","journal-title":"Cell Rep Med"},{"issue":"43","key":"11681_CR86","doi-asserted-by":"publisher","first-page":"e11144","DOI":"10.1002\/advs.202511144","volume":"12","author":"L Zhang","year":"2025","unstructured":"Zhang L, Sun S, Wang D, Yang N, Wang D, Nie J et al (2025) Lactate-modulating nanoreactors facilitate self-amplifying pyroptosis and the cGAS-STING cascade for potentiated catalytic-immunotherapy. Adv Sci (Weinh) 12(43):e11144","journal-title":"Adv Sci (Weinh)"},{"issue":"47","key":"11681_CR87","doi-asserted-by":"publisher","first-page":"e2410336","DOI":"10.1002\/advs.202410336","volume":"11","author":"H Yin","year":"2024","unstructured":"Yin H, Chen T, Hu X, Zhu W, Li Y, Sun W et al (2024) Pyroptosis-inducing biomaterials pave the way for transformative antitumor immunotherapy. Adv Sci (Weinh) 11(47):e2410336","journal-title":"Adv Sci (Weinh)"},{"key":"11681_CR88","doi-asserted-by":"publisher","first-page":"115755","DOI":"10.1016\/j.addr.2025.115755","volume":"229","author":"X Gou","year":"2025","unstructured":"Gou X, He S, Wang B, Zhang L, Cheng Y, Gao X (2025) Integrating PROTAC-based targeted protein degradation with nanodelivery systems to overcome cancer therapeutic resistance. Adv Drug Deliv Rev 229:115755","journal-title":"Adv Drug Deliv Rev"},{"issue":"20","key":"11681_CR89","doi-asserted-by":"publisher","first-page":"e2204031","DOI":"10.1002\/smll.202204031","volume":"19","author":"Y Xing","year":"2023","unstructured":"Xing Y, Zhang F, Ji P, Wei M, Yin C, Yang A et al (2023) Efficient delivery of GSDMD-N mRNA by engineered extracellular vesicles induces pyroptosis for enhanced immunotherapy. Small 19(20):e2204031","journal-title":"Small"},{"key":"11681_CR90","doi-asserted-by":"publisher","first-page":"122894","DOI":"10.1016\/j.biomaterials.2024.122894","volume":"315","author":"K Gao","year":"2025","unstructured":"Gao K, Xi W, Ni J, Jiang J, Lei Y, Li L et al (2025) Genetically modified extracellular vesicles loaded with activated gasdermin D potentially inhibit prostate-specific membrane antigen-positive prostate carcinoma growth and enhance immunotherapy. Biomaterials 315:122894","journal-title":"Biomaterials"},{"key":"11681_CR91","doi-asserted-by":"publisher","first-page":"118433","DOI":"10.1016\/j.ejmech.2025.118433","volume":"303","author":"NS Butakova","year":"2025","unstructured":"Butakova NS, Uspenskaia AA, Zyk NY, Petrov SA, Popovicheva KA, Lunev AS et al (2025) A series of conjugates based on prostate-specific membrane antigen ligands with the chelating agent DOTA: synthesis, radiolabeling, and biological activity. Eur J Med Chem 303:118433","journal-title":"Eur J Med Chem"},{"issue":"28","key":"11681_CR92","doi-asserted-by":"publisher","first-page":"e2302422","DOI":"10.1002\/advs.202302422","volume":"10","author":"H Wang","year":"2023","unstructured":"Wang H, He Z, Gao Y, Feng D, Wei X, Huang Y et al (2023) Dual-pronged attack: pH-driven membrane-anchored NIR dual-type nano-photosensitizer excites immunogenic pyroptosis and sequester immune checkpoint for enhanced prostate cancer photo-immunotherapy. Adv Sci (Weinh) 10(28):e2302422","journal-title":"Adv Sci (Weinh)"},{"issue":"4","key":"11681_CR93","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1080\/1061186X.2024.2433560","volume":"33","author":"X Yang","year":"2025","unstructured":"Yang X, Hu J, Gao Q, Deng Y, Liu Y, He X et al (2025) Advances in nano-delivery systems based on diagnosis and theranostics strategy for atherosclerosis. J Drug Target 33(4):492\u2013507","journal-title":"J Drug Target"},{"issue":"4","key":"11681_CR94","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1021\/acs.accounts.4c00738","volume":"58","author":"X Li","year":"2025","unstructured":"Li X, Qin Z, Wang S, Zhang L, Jiang X (2025) Microfluidics-assembled nanovesicles for nucleic acid delivery. Acc Chem Res 58(4):570\u2013582","journal-title":"Acc Chem Res"},{"issue":"5","key":"11681_CR95","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41580-023-00689-6","volume":"25","author":"J Yuan","year":"2024","unstructured":"Yuan J, Ofengeim D (2024) A guide to cell death pathways. Nat Rev Mol Cell Biol 25(5):379\u2013395","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6","key":"11681_CR96","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1158\/0008-5472.CAN-20-3477","volume":"81","author":"A Ghoochani","year":"2021","unstructured":"Ghoochani A, Hsu EC, Aslan M, Rice MA, Nguyen HM, Brooks JD et al (2021) Ferroptosis inducers are a novel therapeutic approach for advanced prostate cancer. Cancer Res 81(6):1583\u20131594","journal-title":"Cancer Res"},{"key":"11681_CR97","doi-asserted-by":"publisher","first-page":"100985","DOI":"10.1016\/j.drup.2023.100985","volume":"70","author":"J Wang","year":"2023","unstructured":"Wang J, Zeng L, Wu N, Liang Y, Jin J, Fan M et al (2023) Inhibition of phosphoglycerate dehydrogenase induces ferroptosis and overcomes enzalutamide resistance in castration-resistant prostate cancer cells. Drug Resist Updat 70:100985","journal-title":"Drug Resist Updat"},{"key":"11681_CR98","doi-asserted-by":"publisher","first-page":"104907","DOI":"10.1016\/j.critrevonc.2025.104907","volume":"214","author":"M Ebrahimnezhad","year":"2025","unstructured":"Ebrahimnezhad M, Valizadeh A, Yousefi B (2025) Ferroptosis and immunotherapy: Breaking barriers in cancer treatment resistance. Crit Rev Oncol Hematol 214:104907","journal-title":"Crit Rev Oncol Hematol"},{"issue":"8","key":"11681_CR99","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41419-024-06939-5","volume":"15","author":"X An","year":"2024","unstructured":"An X, Yu W, Liu J, Tang D, Yang L, Chen X (2024) Oxidative cell death in cancer: mechanisms and therapeutic opportunities. Cell Death Dis 15(8):556","journal-title":"Cell Death Dis"},{"issue":"10","key":"11681_CR100","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1080\/15548627.2023.2218764","volume":"19","author":"Y Xie","year":"2023","unstructured":"Xie Y, Kang R, Klionsky DJ, Tang D (2023) GPX4 in cell death, autophagy, and disease. Autophagy 19(10):2621\u20132638","journal-title":"Autophagy"},{"issue":"9","key":"11681_CR101","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1038\/s41423-021-00740-6","volume":"18","author":"Y Huang","year":"2021","unstructured":"Huang Y, Xu W, Zhou R (2021) NLRP3 inflammasome activation and cell death. Cell Mol Immunol 18(9):2114\u20132127","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"11681_CR102","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12943-024-02217-2","volume":"24","author":"P Zhao","year":"2025","unstructured":"Zhao P, Yin S, Qiu Y, Sun C, Yu H (2025) Ferroptosis and pyroptosis are connected through autophagy: a new perspective of overcoming drug resistance. Mol Cancer 24(1):23","journal-title":"Mol Cancer"},{"key":"11681_CR103","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jare.2024.12.028","volume":"76","author":"L Ding","year":"2025","unstructured":"Ding L, Zhang R, Du W, Wang Q, Pei D (2025) The role of cGAS-STING signaling pathway in ferroptosis. J Adv Res 76:219\u2013231","journal-title":"J Adv Res"},{"issue":"1","key":"11681_CR104","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1038\/s41467-025-58124-7","volume":"16","author":"L Zhu","year":"2025","unstructured":"Zhu L, Hu J, Wu X, Zhang J, Xu X, Huang X et al (2025) Programmed enhancement of endogenous iron-mediated lysosomal membrane permeabilization for tumor ferroptosis\/pyroptosis dual-induction. Nat Commun 16(1):3017","journal-title":"Nat Commun"},{"issue":"1","key":"11681_CR105","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41391-024-00933-w","volume":"29","author":"H Chen","year":"2026","unstructured":"Chen H, Lyu F, Gao X (2026) Advances in ferroptosis for castration-resistant prostate cancer treatment: novel drug targets and combination therapy strategies. Prostate Cancer Prostatic Dis 29(1):36\u201346","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"12","key":"11681_CR106","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1002\/ijc.33390","volume":"148","author":"E De Schutter","year":"2021","unstructured":"De Schutter E, Croes L, Ibrahim J, Pauwels P, Op de Beeck K, Vandenabeele P et al (2021) GSDME and its role in cancer: From behind the scenes to the front of the stage. Int J Cancer 148(12):2872\u20132883","journal-title":"Int J Cancer"},{"issue":"5","key":"11681_CR107","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.trecan.2020.12.002","volume":"7","author":"J Ibrahim","year":"2021","unstructured":"Ibrahim J, De Schutter E, Op de Beeck K (2021) GSDME: a potential ally in cancer detection and treatment. Trends Cancer 7(5):392\u2013394","journal-title":"Trends Cancer"},{"issue":"1","key":"11681_CR108","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1038\/s41420-025-02733-0","volume":"11","author":"J Xu","year":"2025","unstructured":"Xu J, Fu M, Xing Y, Liang W, Li G, Zhang T et al (2025) Chemically induced dimerization of GSDMD C-terminal domain blocks GSDMD N-terminal domain-mediated pyroptosis. Cell Death Discov 11(1):456","journal-title":"Cell Death Discov"},{"issue":"12","key":"11681_CR109","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1038\/s41423-024-01231-0","volume":"21","author":"S Chen","year":"2024","unstructured":"Chen S, Zhang P, Zhu G, Wang B, Cai J, Song L et al (2024) Targeting GSDME-mediated macrophage polarization for enhanced antitumor immunity in hepatocellular carcinoma. Cell Mol Immunol 21(12):1505\u20131521","journal-title":"Cell Mol Immunol"},{"key":"11681_CR110","doi-asserted-by":"publisher","first-page":"1062225","DOI":"10.3389\/fimmu.2022.1062225","volume":"13","author":"M Khan","year":"2022","unstructured":"Khan M, Ai M, Du K, Song J, Wang B, Lin J et al (2022) Pyroptosis relates to tumor microenvironment remodeling and prognosis: A pan-cancer perspective. Front Immunol 13:1062225","journal-title":"Front Immunol"},{"issue":"13","key":"11681_CR111","doi-asserted-by":"publisher","first-page":"e2417022","DOI":"10.1002\/advs.202417022","volume":"12","author":"Q Gao","year":"2025","unstructured":"Gao Q, Sheng Q, Yang Z, Zhu Z, Li L, Xu L et al (2025) Honokiol-magnolol-baicalin possesses synergistic anticancer potential and enhances the efficacy of anti-PD-1 immunotherapy in colorectal cancer by triggering GSDME-dependent pyroptosis. Adv Sci (Weinh) 12(13):e2417022","journal-title":"Adv Sci (Weinh)"},{"key":"11681_CR112","doi-asserted-by":"publisher","first-page":"1082165","DOI":"10.3389\/fimmu.2023.1082165","volume":"14","author":"Q Kong","year":"2023","unstructured":"Kong Q, Zhang Z (2023) Cancer-associated pyroptosis: A new license to kill tumor. Front Immunol 14:1082165","journal-title":"Front Immunol"},{"key":"11681_CR113","first-page":"537","volume":"41","author":"I Wolf","year":"2024","unstructured":"Wolf I, Storz J, Schultze-Seemann S, Esser PR, Martin SF, Lauw S et al (2024) A new silicon phthalocyanine dye induces pyroptosis in prostate cancer cells during photoimmunotherapy. Bioact Mater 41:537\u2013552","journal-title":"Bioact Mater"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11681-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-11681-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11681-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T12:02:38Z","timestamp":1773662558000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-11681-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":113,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11681"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-11681-6","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]},"assertion":[{"value":"16 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"496"}}